Joan Spanks

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

Tara L. Kieffer, S. Zeuzem, J. Sullivan, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

Tara L. Kieffer, S. Zeuzem, J. Sullivan, 2011 .

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, A. Kwong, S. Zeuzem, 2012, PloS one.

Genotypic and Phenotypic Analyses of Hepatitis C Virus Variants Observed in Clinical Studies of VX-222, a Nonnucleoside NS5B Polymerase Inhibitor

Tara L. Kieffer, B. G. Rao, O. Nicolas, 2014, Antimicrobial Agents and Chemotherapy.

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment

Eric L. Haseltine, Andrew Davis, Tara L. Kieffer, 2014, PLoS Comput. Biol..

1184 CHARACTERIZATION OF HCV VARIANTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS ADMINISTERED THE COMBINATION OF TVR AND VX-222 IN DUAL ARMS OF ZENITH STUDY

A. Bisceglie, D. Bartels, M. Koziel, 2012 .